Quality of surgical care of Canadian patients with pancreatic Introduction: cancer (PC) is inadequately known. Primary aim of this study was to analyze the quality of care received by patients who underwent resections of PC in Nova Scotia over a 10-year period (2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011).
Introduction
Pancreatic cancer (PC) is one of the most common gastrointestinal malignancies in North America and Europe 1, 2 . In comparison to many other malignancies, it has poor prognosis due to late diagnosis and low response to current chemo-radiation therapies 2 . In addition to aggressive biology, recent data also suggest that, within different health systems, the quality of care provided to PC patients is heterogeneous and often suboptimal [3] [4] [5] [6] [7] [8] [9] [10] [11] . In Canada, national data published in 2014 12 revealed that the overall 5-year survival of patients diagnosed with PC correlated with the geographical areas of their residence, with Nova Scotia having the lowest survival rate (4.7% 5-year survival in comparison to the national rate of 9.1%; P<0.05) 13 . Several hypotheses have been raised to explain these findings 11 : lower socio-economic conditions, higher alcohol and tobacco consumption, more sedentary lifestyle and higher prevalence of obesity than in other Canadian provinces [14] [15] [16] . Alternatively, these results might be due to lower quality of care delivered to PC patients living in Nova Scotia where, contrary to several other Canadian provinces, a formal and coordinated quality improvement intervention for PC had never occurred 11 .
The primary aim of this study was to compare the quality of care and outcomes of patients who underwent surgical therapy for PC in Nova Scotia over a 10-year period using disease-specific quality indicators (QIs) published in the scientific literature as references 11, 17 .
Methods

Patient selection
The study population included a cohort of patients older than 18 years of age who had undergone resection for primary exocrine pancreatic cancers (PC) in the province of Nova Scotia, Canada over a 10-year period (April 1, 2001 -March 31, 2011 . Diagnostic codes of the International Classification of Disease for Oncology, 3 rd edition (ICD-O-3) were used to select patients with PC from the Nova Scotia Cancer Registry (NSCR), a prospectively maintained provincial registry of all patients affected by malignant diseases in the province. Diagnostic codes of malignancies of the exocrine pancreas used for this study are summarized in Table 1 . Patients were excluded if affected by pancreatic endocrine neoplasms, lymphomas, sarcomas, metastases from other malignancies or direct invasion of tumors originating in surrounding organs (e.g. retroperitoneum, gastrointestinal tract). 8000, 8001, 8002, 8003, 8010, 8011, 8012, 8020, 8021, 8022, 8030, 8031, 8032, 8033, 8034, 8035, 8050, 8052, 8140, 8141, 8142, 8143, 8144, 8145, 8146, 8147, 8230, 8243, 8245, 8249, 8255, 8260, 8261, 8262, 8263, 8310, 8323, 8440, 8441, 8452, 8453, 8470, 8472, 8473, 8480, 8481, 8490, 8500, 8501, 8502, 8503, 8510, 8550, 8551, 8560, 8570, 8571, 8572, 8573, 8574, 8575, 8576, 8971, 8980 .
ICD Codes Used for Identification of Tumors Origination from Endocrine Pancreatic Cells ICD-O-3 Histology Codes
Islet Cell Carcinoma Beta- 8150, 8151, 8152, 8155, 8153, 8156, 8157, 8160, 8161, 8240, 8241, 8242, 8246, 8337 Each patient who satisfied the inclusion criteria was assigned an identification (ID) number to protect patients' privacy. Additional administrative datasets were linked to the NSCR for completion of sociodemographic and clinical data as represented in Figure 1 . 18 . These datasets were linked to the NSCR by the Population Health Research Unit (PHRU) at Dalhousie University. The methodology used to link these administrative datasets has been described in details in previous manuscripts published by our group 17, 18 . Surgical patients were excluded if they underwent palliative interventions such as biliary or gastric bypasses when found to be unresectable intraoperatively. .
Selection of quality indicators (QIs)
The quality of surgical care delivered to patients with PC was measured using QIs proposed by Sabater et al. 17 and Bilimoria and colleagues 11 . Quality measures selected from Sabater's study 21 were: perioperative morbidity, perioperative mortality, overall 1, 3 and 5-year survival, number of lymph nodes reported within the surgical specimen and state of resection margins. The international classification of surgical pathologists was used to describe the involvement of resection margins with R0 margins meaning absence of cancer cells seen microscopically, R1 indicating that cancerous cells could be seen microscopically and R2 when tumor tissue was visible at naked eye on the margins at gross examination. Overall survival was recorded at 1, 3, and 5 years after surgery. All causes of death were considered secondary to recurrent disease and patients who were still alive at the closure of this study were censored. The only variation that occurred in reporting perioperative complications in this study was that adverse events were recorded only if satisfied grade III to V of Clavien-Dindo classification 21 contrary to Sabater et al. 17 who recommended reporting all grades of perioperative complications. QIs identified from the study by Bilimoria et al. 11 were summarized in four domains: preoperative, operative, surgical pathology reporting and postoperative outcomes. 
2.
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Statistical analysis The quality of care of patients who underwent surgical resection of PC in Nova Scotia was compared to the mean and 95% confidence interval (CI) of QIs selected by Sabater et al. 17 . In their study, Sabater and colleagues 17 performed a comprehensive search of practice guidelines, consensus conferences and reviews of pancreatic oncologic surgery and selected clinical relevant indicators of quality with weighted averages and respective 95% CIs. Comparisons between Nova Scotia and outcome benchmarks were performed using 95% CI for each of the QIs to test for possible statistically significant differences.
Overall survival analysis was performed using Kaplan-Meier methodology 22 . All statistical analysis was carried out using SAS® (Version 8.2, Cary, North Carolina). Two-tailed analyses were performed unless otherwise specified. Missing data were excluded except when imputation was possible from administrative data. All statistical analyses were considered significant at p<0.05.
Results
Inclusion criteria were satisfied by 109 patients. Fifteen patients (13.7%) were excluded due to significant missing data. As a result, a total of 94 patients were included and represented the study population where the median age was 66.8 years, 41% were female, and 87% underwent a pancreaticoduodenectomy (Table 2 ).
Surgical quality of care
Perioperative complications occurred in 25 patients (24.5%) (95% CI: 16.2-32.8%), and perioperative mortality occurred in 5 (5.9%) (95% CI: 2.2-10.5%). R1 resections occurred in 38 patients (37.3%) (95% CI: 37.2-46.6%) (Figure 2 ). The mean number of lymph node retrieved in each specimen was 9.0 (95% CI: 7.7-10.3) and the overall patient survival at 1, 3, and 5 years was 55.1% (95% CI: 45.2-63.8%), 18.5% (95% CI: 11.5-26.7%), and 9.4% (95% CI: 4.2-17.1%), respectively (Figure 2 ). When data from Nova Scotia were compared to values reported by Sabater et al. 17 , there were no statistically significant differences as 95% CIs overlapped between the two groups except for the mean number of lymph nodes identified in the pathology specimens and the rate of serious complications that were lower for patients operated in Nova Scotia.
Assessment of other QIs proposed by Bilimoria et al. 11 revealed that there was significant heterogeneity in the percentage of Nova Scotia patients who met the QIs across all four different domains (Table 3) . For example, in the preoperative domain, 82% of patients had an appropriate cross-sectional imaging study within 2 months from the day of their surgery and 93% underwent treatment within 2 months after their diagnosis. On the other hand, only 33% of patients had 10 or more lymph nodes identified in the surgical specimen and only 24% had a complete TNM stage description in the final surgical pathology report.
Discussion
In 2014, Statistic Canada 12 published that in Nova Scotia, 5-year overall survival of PC patients was 4.7% in comparison to the national rate of 9.1% 23 . These results confirmed observations from other researchers who reported geographical variations in how PC patients are treated and differences in their overall outcomes. Variations treatments depend on multiple factors including physicians' expertise, hospital resources, and patients' characteristics. For example, other researchers have shown that patients who live in rural areas or who belong to lower socio-economic groups have worse outcomes when diagnosed with complex gastrointestinal malignancies or other chronic diseases 13, 14, [24] [25] [26] . This might be due to barriers to access hospitals or specialists, especially in countries where for-profit organizations play an important role in the delivery of healthcare. In Canada, these potential barriers should not exist as health care services are public and, ideally, equally accessible to all citizens.
In a previous paper 11 , our group suggested the possibility that the lower overall survival of PC patients living in Nova Scotia was due to differences in their socio-demographic characteristics when compared to other Canadian provinces [14] [15] [16] . Unfortunately, the data provided by Statistic Canada were not sufficiently granular to assess patients' characteristics, and we could not exclude that patients diagnosed with PC in Nova Scotia received suboptimal care. Because of these concerns, we carried out an extensive epidemiological study that included all patients diagnosed with PC over a 10-year period in Nova Scotia with the main intent of assessing the quality of their care using established disease-specific indicators.
One of the main findings of this study was that a small proportion of patients underwent surgical treatment during the study period. In fact, among a total number of 1094 patients diagnosed with PC over a ten-year period, only 109 (9.9%) underwent radical surgery. This is in contrast to reports from other Canadian centers where radical surgery was feasible in up to 25% of referrals 15 . Our study, however, has shown that the quality of care of patients who underwent surgery was within the confidence intervals of benchmarks published by Sabater et al. 17 . In other words, there were no significant statistical differences in perioperative mortality, R1 resection rates and overall survival at 1, 3 and at 5-year after surgery between our population and the parameters used for comparison. Nevertheless, there was a trend towards higher perioperative mortality, and overall lower survival rate compared to the pooled data from the scientific literature.
When we analyzed the proportion of patients who met QIs in the four domains proposed by Bilimoria et al. 11 , we found that there were considerable gaps in the quality of surgical pathology reporting and utilization of adjuvant therapies. The quality of pathology reports might have influenced how patients were managed after their operation. In fact, patients with surgical pathology reports that did not mention positive resection margins or lymph node involvement were rarely referred to medical oncologists after their surgeries. The main reason was that in our institution, referral patterns, and medical oncological therapies were not unified and some providers perceived that there was no benefit for postoperative chemotherapy except for patients at high risk of recurrence (e.g. positive resection margins or positive lymph node involvement). Overall, only 53% of patients in our study were referred to medical oncology service for adjuvant therapy, and only 46% ended up to be seen by a medical oncologist.
This study has several limitations due to the retrospective nature of its design and the linking of multiple datasets that could have increased the risks of inaccuracy of the data as the primary purpose of these datasets was not for research 16 . Another important limitation is the small number of patients who were included. The overall number of inhabitants in Nova Scotia has been relatively stable with an estimated population of 930,000. Since the yearly incidence of PC in Canada is in the range of 8-11 patients/100,000 inhabitants 18 , we are confident that the majority of patients diagnosed during the study period were identified. However, the resectability rate was much lower than expected as the majority of referrals were unable to undergo surgery due to the advanced stages of the disease or the presence of severe comorbidities that precluded resections. Since surgery remains the only possible curative treatment for PC, the fact that less than 10% of patients were offered this opportunity raises the doubts that a considerable proportion was diagnosed late or not referred for surgical opinion in a timely fashion.
Despite the above limitations, our study is original and, to the best of our knowledge, it is the first to assess the quality of care provided to patients who underwent surgery for PC at a Canadian provincial level by using established indicators. Also, before this study, there were no reports on the resectability rate of PC in Nova Scotia or the overall 5-year survival of patients who underwent surgery.
In conclusion, patients diagnosed with PC and treated with radical resections in Nova Scotia had acceptable outcomes comparable to published international standards. However, we found that resectability rate was below average and a significant proportion of patients did not meet several QIs including preoperative radiological studies that were older than two months, incomplete surgical pathological reporting and, finally, a low referral rate and utilization of adjuvant therapy. Because survival of patients with PC remains disappointing, it is important to monitor for correctable deficiencies in the health care system. Our study suggests that, in Nova Scotia, there is need to increase early detection and early surgical referral, a more exhaustive pathology reporting and an increased use of adjuvant chemotherapy. A coordinated implementation of all these interventions might improve the overall survival of PC patients in the province. However, areas in which quality improvement strategies are most effective remain unknown and should be explored in future studies.
Data availability
Nova Scotia's Personal Health Information Act, S.N.S. 2010, c 41 (PHIA), a provincial legislation which governs the collection, use, disclosure, retention and disposal and destruction of personal health information of patients treated in Nova Scotia, came into force on June 1 2013 19 . The goal of this statute is to balance the privacy rights of individuals with respect to their personal health information and the need for researchers and practitioners to collect, use and disclose personal health information as part of providing strong healthcare services in Nova 20 . Due to restrictions imposed by PHIA, the raw data used for this study can only be accessible to investigators who obtain permission from Capital Heatlh Research Ethics Board Centre for Clinical Research and from the Nova Scotia Cancer Registry to use the encrypted database.
Investigators should submit their request to access the encrypted database used for this study to: Capital Health Research Ethics Board, Room 322, CCR, 5790 University Avenue, Halifax, NS, B3H 1V7, Canada.
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Given the retrospective, administrative nature of the data, there are inherent limitations such as the lack of detailed information related to post-operative complications and factors that may have influenced referral to surgical and medical oncologists. Moreover, despite using registry data for the entire province of Nova Scotia over 10 years, the actual study cohort is quite small (n=94), limiting more detailed analysis. Perhaps there is a temporal relationship between quality of care and time, with better outcomes in the more recent era? Given the small numbers, it is not possible to explore how quality may have changed over time. Nevertheless, the authors should be commended for the candid reporting of this data, highlighting the insufficiencies in the delivery of care to patients with pancreatic cancer in Nova Scotia. Through their investigation they were able to identify several areas where quality of care can be improved, with a view to achieving better outcomes. This report also underscores the importance of health services research and population-based studies to determine if outcomes in routine practice are indeed comparable to published reports and to identify deficiencies in the health care system in order to better organize, manage and deliver quality care.
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Rachel Foskett-Tharby National Collaborating Centre for Indicator Development, Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK This was an interesting and well written article but the following points of data accuracy and interpretation should be addressed. Table 2 appears to have some missing data. Specifically the numbers of patients reported against each income quartile do not sum to 94. I'm also not sure if the numbers of patients experiencing a grade 5 perioperative complication have been missed from the table.
There is an inconsistency in the numbers of patients with perioperative complications reported in the text on page 5 (25 patients) and those reported in Table 2 (19 patients with grade 3 and 4 classifications of complications).
The final sentence of paragraph 2 of the results states that there was a statistically significant difference in perioperative morbidity between Nova Scotia and the Sabater et al study. Surely this has occurred not as a result of differences in practice but due to the differences in definition of perioperative morbidity between the studies. This comparison should be recalculated using the same definition (i.e. all grades of the Dindo-Clavien Classification of Perioperative Adverse Events) as the Sabater study and appropriate conclusions drawn. et al, 
